

Insulin Toujeo (insulin glargine) 300 units per ml

NB. This guidance has been updated to allow for a wider group of clinicians to prescribe
September 2019 update: To include differences of SOLOstar and DOUBLEstar device

Recommendation

Insulin Toujeo (insulin glargine) 300 units per ml has been approved for use for the following patients:

- Patients requiring doses of insulin which exceed the end of their current delivery device (typically 60 to 80 units per day)
- Patients who experience difficulty with injections at doses greater than 40 units per day may also be considered for Toujeo on an individual patient basis.
- The Insulin Toujeo DOUBLEstar device can be considered for those patients needing larger volumes of Toujeo device

Insulin Toujeo is available as 2 devices both the SOLOstar and DOUBLEstar device. Healthcare professionals must be aware of the difference between these devices. The SOLOstar device delivers 1 unit of insulin per “click”. The DOUBLEstar device delivers 2 units of insulin per click. When prescribing care must be taken to ensure that the device being prescribed is the device the patient is trained on and is aware of how to use either device.

Packaging is different between the Solostar and Doublestar device (see attachment below). All clinicians prescribing from clinical systems must take extra care that the right device is selected.

Toujeo DOUBLEstar device **should not be prescribed to** those patients who are visually impaired and who self-administer insulin.

Toujeo is not bioequivalent to Lantus and dose adjustment is needed when switching from Lantus or other basal insulins to Toujeo.

As with all insulins Toujeo Solostar or Doublestar must be prescribed by brand to avoid inadvertent switching to Lantus, Abasaglar or other brand of insulin glargine.

It would be expected that any clinician initiating the prescribing Toujeo following this recommendation would have completed relevant training such as PITstop or other, to ensure they are competent.

Toujeo is a high strength formulation of insulin glargine (300 units per ml). It is licensed for use in both type 1 and type 2 patients with diabetes.

Toujeo is available in a pack containing 3 pens. Each Solostar pen contains 1.5 ml of insulin glargine 300 units/ml solution for injection, equivalent to 450 units. Each Doublestar pen contain 3ml of insulin glargine 300 units/ml solution for injection, equivalent to 900 units.

NICE guidelines on management of type 1 diabetes (NG17) recommend insulin detemir twice a day as the preferred basal therapy. Insulin glargine once a day is recommended as an alternative treatment.
NICE guidelines on management of type 2 diabetes (NG28) recommend NPH insulin as the preferred basal therapy. Insulin glargine or insulin detemir are recommended alternatives in certain circumstances.

Further training can be provided through:

- PITstop training: any GP or nurse interested can contact KCHFT via the education email for a registration form, Tel: 01233 667775, email: kcht.diabeteseducation@nhs.net.
- Sanofi – Lorraine Beverley, Executive Primary Care Diabetes Specialist, Tel: 07919 044065, email: Lorraine.Beverley@sanofi.com

Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

Date: September 2017

Address: c/o Canterbury and Coastal CCG, Brook House, John Wilson Business Park, Whitstable, CT5 3DD

Contact: T: 01227 791267 | E: accg.eastkentprescribing@nhs.net

[Appendix 1: Information on Toujeo doublestar device](#)



HCP Letter.pdf



HCP.pdf



Patient & Carers.pdf

<https://www.medicines.org.uk/emc/product/10277/rmms>

Approved by: East Kent Prescribing Group (*Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG*)

Date: September 2017

Address: c/o Canterbury and Coastal CCG, Brook House, John Wilson Business Park, Whitstable, CT5 3DD

Contact: T: 01227 791267 | E: accg.eastkentprescribing@nhs.net